Tedisamil

Summary

Tedisamil (CHEMBL113461) is a phase-3 clinical-stage small molecule (ATC C01BD06) targeting KCNA7; indicated across 1 condition.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• ATC class: C01BD06
• Targets: 1 (KCNA7)
• Indications: 1 condition
• Chemistry: 288.5 Da · C19H32N2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL113461
Name	Tedisamil
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	65825
ATC	C01BD06
Molecular formula	C19H32N2
Molecular weight	288.5
InChIKey	CTIRHWCPXYGDGF-UHFFFAOYSA-N

SMILES: C1CCC2(C1)C3CN(CC2CN(C3)CC4CC4)CC5CC5

IUPAC name: 3,7-bis(cyclopropylmethyl)spiro[3,7-diazabicyclo[3.3.1]nonane-9,1’-cyclopentane]

Also known as: KC-8857, KC8857, Tedisamil, TEDISAMIL

Parent form; salt/anhydrous children: CHEMBL2107378

Patent coverage: 366 distinct patent families (1,251 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).

Gene	Target	Action	pAffinity	Cancer dependency	UniProt
KCNA7	Kv1.7		4.7	0.5%	Q96RP8

Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: Sodium channel alpha subunit, Voltage-gated inwardly rectifying potassium channel KCNH2.

Bioactivity

ChEMBL activities: 1 potent at pChembl ≥ 5 of 2 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
KCNH2	5.6	IC50	2500	nM	CHEMBL_ACT_15257975

Target pathways

Aggregated over 1 target gene(s): KCNA7.

Top Reactome pathways

3 total, by targets touching each:

Pathway	Targets	Genes
Neuronal System	1	KCNA7
Potassium Channels	1	KCNA7
Voltage gated Potassium channels	1	KCNA7

Dominant GO biological processes

GO term	Targets
action potential	1
protein homooligomerization	1
potassium ion transmembrane transport	1
monoatomic ion transport	1
potassium ion transport	1
monoatomic ion transmembrane transport	1
transmembrane transport	1

Indications & clinical

Indications

1 indication (0 at ChEMBL trial phase 4).

The 1 indication record carries no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.

4 molecules share ≥1 primary target. Top 4 by shared-target count:

Molecule	Source	Status	Shared targets
Amiodarone	PubChem	Approved	KCNA7
Flecainide	PubChem	Approved	KCNA7
Quinidine	PubChem	Approved	KCNA7
Verapamil	PubChem	Approved	KCNA7